Debbie Avant1, Gerri Baer1, Jason Moore2,3, Panli Zheng4, Alfred Sorbello5, Ron Ariagno1,6, Lynne Yao7, Gilbert J Burckart2, Jian Wang8. 1. Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA. 2. Office of Clinical Pharmacology, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD, USA. 3. Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA. 4. University of North Carolina School of Pharmacy, Chapel Hill, NC, USA. 5. Office of Translational Sciences, US Food and Drug Administration, Silver Spring, MD, USA. 6. Stanford University School of Medicine, Stanford, CA, USA. 7. Division of Pediatric and Maternal Health, Office of New Drugs, CDER, US Food and Drug Administration, Silver Spring, MD, USA. 8. Office of Drug Evaluation IV, CDER, US Food and Drug Administration, Silver Spring, MD, USA.
Abstract
BACKGROUND: Relatively few neonatal drug development studies have been conducted, but an increase is expected with the enactment of the Food and Drug Administration Safety and Innovation Act (FDASIA). Understanding the safety of drugs studied in neonates is complicated by the unique nature of the population and the level of illness. The objective of this study was to examine neonatal safety data submitted to the FDA in studies pursuant to the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) between 1998 and 2015. METHODS: FDA databases were searched for BPCA and/or PREA studies that enrolled neonates. Studies that enrolled a minimum of 3 neonates were analyzed for the presence and content of neonatal safety data. RESULTS: The analysis identified 40 drugs that were studied in 3 or more neonates. Of the 40 drugs, 36 drugs received a pediatric labeling change as a result of studies between 1998 and 2015, that included information from studies including neonates. Fourteen drugs were approved for use in neonates. Clinical trials for 20 of the drugs reported serious adverse events (SAEs) in neonates. The SAEs primarily involved cardiovascular events such as bradycardia and/or hypotension or laboratory abnormalities such as anemia, neutropenia, and electrolyte disturbances. Deaths were reported during studies of 9 drugs. CONCLUSIONS: Our analysis revealed that SAEs were reported in studies involving 20 of the 40 drugs evaluated in neonates, with deaths identified in 9 of those studies. Patients enrolled in studies were often critically ill, which complicated determination of whether an adverse event was drug-related. We conclude that the traditional means for collecting safety information in drug development trials needs to be adjusted for neonates and will require the collaboration of regulators, industry, and the clinical and research communities to establish appropriate definitions and reporting strategies for the neonatal population.
BACKGROUND: Relatively few neonatal drug development studies have been conducted, but an increase is expected with the enactment of the Food and Drug Administration Safety and Innovation Act (FDASIA). Understanding the safety of drugs studied in neonates is complicated by the unique nature of the population and the level of illness. The objective of this study was to examine neonatal safety data submitted to the FDA in studies pursuant to the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) between 1998 and 2015. METHODS: FDA databases were searched for BPCA and/or PREA studies that enrolled neonates. Studies that enrolled a minimum of 3 neonates were analyzed for the presence and content of neonatal safety data. RESULTS: The analysis identified 40 drugs that were studied in 3 or more neonates. Of the 40 drugs, 36 drugs received a pediatric labeling change as a result of studies between 1998 and 2015, that included information from studies including neonates. Fourteen drugs were approved for use in neonates. Clinical trials for 20 of the drugs reported serious adverse events (SAEs) in neonates. The SAEs primarily involved cardiovascular events such as bradycardia and/or hypotension or laboratory abnormalities such as anemia, neutropenia, and electrolyte disturbances. Deaths were reported during studies of 9 drugs. CONCLUSIONS: Our analysis revealed that SAEs were reported in studies involving 20 of the 40 drugs evaluated in neonates, with deaths identified in 9 of those studies. Patients enrolled in studies were often critically ill, which complicated determination of whether an adverse event was drug-related. We conclude that the traditional means for collecting safety information in drug development trials needs to be adjusted for neonates and will require the collaboration of regulators, industry, and the clinical and research communities to establish appropriate definitions and reporting strategies for the neonatal population.
Entities:
Keywords:
US FDA; drug development; neonates; safety; serious adverse events
Authors: Asia N Rashed; Ian C K Wong; Noel Cranswick; Stephen Tomlin; Wolfgang Rascher; Antje Neubert Journal: Eur J Clin Pharmacol Date: 2011-12-14 Impact factor: 2.953
Authors: Roberta A Ballard; William E Truog; Avital Cnaan; Richard J Martin; Philip L Ballard; Jeffrey D Merrill; Michele C Walsh; David J Durand; Dennis E Mayock; Eric C Eichenwald; Donald R Null; Mark L Hudak; Asha R Puri; Sergio G Golombek; Sherry E Courtney; Dan L Stewart; Stephen E Welty; Roderic H Phibbs; Anna Maria Hibbs; Xianqun Luan; Sandra R Wadlinger; Jeanette M Asselin; Christine E Coburn Journal: N Engl J Med Date: 2006-07-27 Impact factor: 91.245
Authors: Matthew M Laughon; Debbie Avant; Nidhi Tripathi; Christoph P Hornik; Michael Cohen-Wolkowiez; Reese H Clark; P Brian Smith; William Rodriguez Journal: JAMA Pediatr Date: 2014-02 Impact factor: 16.193
Authors: Jeremiah D Momper; Jin Yang; Mary Gockenbach; Florin Vaida; Sanjay K Nigam Journal: Clin J Am Soc Nephrol Date: 2019-03-18 Impact factor: 8.237